Is this stock market theme a big opportunity or a bubble?
A new generation of weight-loss drugs have proved appetising to investors, with the two companies currently dominating the market enjoying strong share price gains over the past few years. Other firms are also poised to join the trend, which is expected to expand significantly by 2030. However, does the hype risk…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from On The Money
See all episodes →Similar episodes from other shows
More like On The Money →
54%Where to find healthy profits in biotech
Investing in weight-loss drugs, and why everyone’s talking about student loans
Money Talks: Why weight-loss drugs will reshape the world
Novo Nordisk, Eli Lilly and the GLP-1 economy
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.